-
In order to get out of the "inner volume", domestic pharmaceutical company license-out will continue to be hot!
Time of Update: 2023-02-01
(Image source: Pharma Network) It is reported that the exclusive transfer right agreement contains the license terms negotiated between SignNova and AmMax. At the same time, in accordance with this agreement, the two parties will collaborate to complete the clinical trial application (IND) of the collaborative project and the design of the dose-escalation clinical study, which is expected to be submitted to the IND application in China and the United States in mid-2023.
-
This week, a large number of domestic pharmaceutical companies announced that new drugs have been approved for clinical trials
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];Recently, Saisheng Pharmaceutical issued an announcement that the company received the notice of approval of the supplementary application for clinical trial of humanized anti-VEGF monoclonal antibody injection issued by the National Medical Products Administration.
-
The Medical Insurance Bureau issued a "pricing mechanism" for new crown drugs: considering the cost and clinical value, but Lianhua Qingwei was not affected
Time of Update: 2023-02-01
According to the Notice, the pricing of new crown treatment drugs needs to take into account cost factors, including "raw material costs, research and development expenses, and period costs", and also fully consider "innovation" and "economy".
-
Notice on public solicitation of opinions on the "Technical Guidelines for the Research of Improved New Drugs of Traditional Chinese Medicine (Draft for Comments)"
Time of Update: 2023-02-01
Notice on public solicitation of opinions on the "Technical Guidelines for the Research of Improved New Drugs of Traditional Chinese Medicine (Draft for Comments)"Release date: 20230106 According to
-
How can Shanghai break the shortage of elderly care talents and cope with the aging society?
Time of Update: 2023-02-01
and other special elderly people According to the survey of the Shanghai Municipal Committee of the Jiusan Society, most of the services provided by the "long-term care insurance" elderly in Shanghai are domestic care workers, who generally have a low level of knowledge and insufficient practical ability, and the content of home economics and elderly care training is difficult to cope with daily nursing work, and the service quality cannot be guaranteed.
-
Inventory of the 2022 Ministry of Science and Technology major scientific instrument research and development special project plan high-end instrument research and development
Time of Update: 2023-02-01
Innovation is the need for the development of science and technology and social production, which will promote the development and change of analytical chemistry. As an important tool for scientific
-
The Chinese market is promising, what are the localization strategies of foreign instrument companies?
Time of Update: 2023-02-01
14 pharmaceutical companies, including Dirui Medical, were investigated [ News Search ] [ Add to favorites ] [ Tell a friend ] [ Print this article ] [ Close Window ] Similar information January 7, 2022, Agilent announced that it will expand production and capabilities at its Shanghai manufacturing center, invest in expanding production of advanced technology products such as liquid chromatograph (LC), spectrometer, and mass spectrometer (MS) systems, and further enhance Agilent's manufacturing capabilities in China.
-
AstraZeneca's $1.8 billion acquisition! Why is Cincor just one year on the market?
Time of Update: 2023-02-01
1It has only been on the market for one yearGet market focus with Baxdrostat Founded in 2018, CinCor is a clinical-stage biopharmaceutical company based in the United States focused on developing novel therapies for refractory and uncontrolled hypertension and chronic kidney disease.
-
Notice on public solicitation of comments on the Catalogue of Reference Preparations for Chemical Generic Drugs (66th Batch) (Draft for Comments).
Time of Update: 2023-02-01
Center for Drug Evaluation, State Medical Products Administration January 09, 2023 Related attachments serial number Attachment name 1 The Catalogue of Reference Preparations for Chemical Generic Drugs (Batch 66) (Draft for Comments) .
-
2022 inventory of 227 IND varieties declared for the first time for domestic Class 1 new drugs, Hengrui leading, Qilu, East Sunshine...
Time of Update: 2023-02-01
, is an innovative, oral small molecule HIF-2α inhibitor clinically intended for the treatment of patients with advanced solid tumors.
, is an innovative, oral small molecule HIF-2α inhibitor clinically intended for the treatment of patients with advanced solid tumors.
-
In 2023, the leading companies of conventional vaccines may usher in a larger market increment
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];Kangtai Biotechnology, a leading domestic vaccine company, released its 2022 performance forecast on the evening of January 10, and it is expected that the net profit attributable to shareholders of listed companies in 2022 will be a loss of 76 million yuan ~ 150 million yuan, down 106.
-
In 2023, "Golden Eye" is expected to return, and ophthalmic companies may maintain a high degree of prosperity
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];Recently, some institutions pointed out that the current investment in the pharmaceutical sector will gradually return to the main business, focusing on consumer medical care.
js?cdnversion='+~(-new Date()/36e5)];Recently, some institutions pointed out that the current investment in the pharmaceutical sector will gradually return to the main business, focusing on consumer medical care.
-
The second batch of national key monitoring and rational drug use drugs catalogue was issued
Time of Update: 2023-02-01
Health commissions of all provinces, autonomous regions, municipalities directly under the Central Government and the Xinjiang Production and Construction Corps: In order to further strengthen the management of clinical rational drug use in China, according to the "National Key Monitoring Rational Drug List Adjustment Work Regulations" (National Health Office Medical Letter [2021] No. 474), our committee determined the "Second Batch of National Key Monitoring and Rational Drug Use Drug List" (hereinafter referred to as the "Catalogue").
-
In the "height" market of tens of billions of yuan, the product research and development of many pharmaceutical companies has ushered in new progress
Time of Update: 2023-02-01
Recently, Changchun High-tech issued the "Announcement on the Approval of New Indications of Recombinant Human Growth Hormone Injection of Holding Subsidiaries" (hereinafter referred to as the "Announcement"), and the approved and increased indication of the drug is prepubertal growth disorder caused by chronic kidney disease (CKD).
-
The new coronavirus treatment drug monoravir capsules completed the first batch of import customs clearance in the Shanghai Waigaoqiao Free Trade Zone
Time of Update: 2023-02-01
The new coronavirus treatment drug monoravir capsules completed the first batch of import customs clearance in the Waigaoqiao Free Trade Zone in Shanghai on the 13th.
The new coronavirus treatment drug monoravir capsules completed the first batch of import customs clearance in the Waigaoqiao Free Trade Zone in Shanghai on the 13th.
-
Since January, the cumulative transaction turnover of the pharmaceutical industry has exceeded 10 billion, and Hengrui has "won the championship"
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];Data show that as of January 15, a total of 1,871 large transactions have occurred in the A-share market since 2023, with a cumulative transaction volume of 2.
-
Can I participate in "Beijing Universal Health Insurance" with medical insurance from other places? Here comes the Q&A
Time of Update: 2023-01-06
A: Yes. When enrolling, what does the prompt "Please confirm whether the insured is the following groups", [new citizens, public medical care, and other medical insurance conditions that can participate in Beijing Universal Health Insurance]?
-
Another domestic anti-cancer new drug approved for marketing!
Time of Update: 2023-01-06
, Ltd. announced that the company's self-developed new anti-cancer class 1 drug linperlisib has been approved by China's National Medical Products Administration (NMPA) on November 9, targeting the treatment of relapsed/refractory (R/R) follicular lymphoma (FL) under the trade name Intaru.
-
Pharmaceutical equipment companies are working hard to sprint to the fourth quarter!
Time of Update: 2023-01-06
【Pharmaceutical Network Industry News】For pharmaceutical equipment companies, the fourth quarter is a key period to complete the annual target tasks, and there is no room for any relaxation. Recently,
-
Pharmaceutical equipment companies are working hard to sprint to the fourth quarter!
Time of Update: 2023-01-06
【Pharmaceutical Network Industry News】For pharmaceutical equipment companies, the fourth quarter is a key period to complete the annual target tasks, and there is no room for any relaxation. Recently,
